Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven, newly diagnosed pancreatic adenocarcinoma or adenosquamous carcinoma~* no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, or immunotherapy used for pancreatic cancer~* presence of at least one measurable lesion, which must meet the criteria of being ≥ 20 mm in at least one dimension by conventional CT/MRI or ≥ 10 mm by spiral CT scan~* age between 20 and 79 years at registration~* ECOG PS of 0 or 1~* adequate major organ functions~* ability to take the oral study medication (TS-1)~* no clinically significant abnormal ECG findings within 28 days (4 weeks) prior to registration~* voluntarily signed the written informed consent form~Exclusion Criteria:~* pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to registration~* presence of diarrhea ≥ CTCAE v.4.03 grade 2~* concomitant active infection or significant co-morbid medical conditions~* moderate or severe ascites or pleural effusion that requires drainage~* central nervous system metastasis~* prior or concurrent malignancies within the last 3 years~* concomitant treatment with flucytosine, phenytoin or warfarin~* pregnant women or nursing mothers, or positive pregnancy test~* severe mental disorder~* judged ineligible by physician for participation in the study due to safety concern

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- S-1-CCRT (Type: EXPERIMENTAL): There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT

Based on this trial design, predict the completion outcome and termination type (if applicable).